Drugs / GEH121224
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05634954 | Feb → Dec 2026 | breast cancer | GE Healthcare | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEH121224 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05634954 ↗ |
| Known as | [18F]GEH121224 | “[18F]GEH121224 PET imaging” NCT05634954 ↗ |
| Modality | Diagnostic / imaging agent | “as a PET radiotracer for the diagnostic imaging of HER2 positive breast cancer lesions” NCT05634954 ↗ |